Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.
KUALA LUMPUR: Pharmaceutical firm Duopharma Biotech Bhd, through wholly-owned subsidiary Duopharma HAPI Sdn Bhd, will soon manufacture its second oncology drug at its first-in-Malaysia highly potent active pharmaceutical ingredient (HAPI) Plant in Shah Alam to help address the paucity of affordable alternatives to treat cancer.
Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.
The HAPI plant is equipped to produce a wide portfolio of cancer medicines to help to treat, among others, breast cancer, lung cancer, colorectal cancer, cervical cancer, and blood cancer, making it the first cancer medicine manufacturing facility in Malaysia.
Duopharma Biotech group is embracing innovation and technology to serve patients who need specific and targeted therapies that can be produced by our new state-of-the-art HAPI Plant, he said in a statement to Bernama today.
The facility is also fully capable of producing medicines to treat hormonal imbalance and highly potent medicines for cardiovascular, central nervous system and musculoskeletal diseases. In the first quarter of this year, Duopharma Biotech successfully manufactured and commercialised its first product (letrozole), which is prescribed for breast cancer treatment.
Leonard Ariff revealed that the HAPI plant’s next product would be the first locally manufactured drug to treat chronic myeloid leukemia for both adults and children.
"The medicine which will be produced locally is targeted to be commercialised in due course,” he said.
This medicine produced at the HAPI plant, which is available at an affordable price, will enable patients especially in the low and middle income categories to have access to the treatment.
"Affordability and access issues are especially prevalent amongst the financially challenged and there is evidence that out-of-pocket costs for such prescription drugs to treat chronic diseases not only impose a financial burden but result in reduction in medication adherence leading to worsening health outcomes.
"Our objective in establishing the HAPI plant in Malaysia is premised on a mission to offer medication to address the lack of alternatives while delivering equitable and affordable access to prescription medications. The plant will also provide some level of self-sufficiency to the country in terms of the specific oncology medications,” he said.
The HAPI facility is a Good Manufacturing Practice certified plant by the Malaysian National Pharmaceutical Regulatory Agency (NPRA). This ensures that production and quality control consistently meet the highest standards.
Duopharma Biotech is also currently engaging with pharmaceutical companies across the globe to bring high-end technologies and allowing for technology transfer which enables it to locally manufacture high-value drugs.
This is expected to further strengthen the company’s position as the leading pharmaceutical player in Malaysia, and help it achieve its target of being a leading pharmaceutical company in Southeast Asia.
"We are widening our product portfolio by offering not just oncology medicines but also psychotropic drugs, which is an emerging market in Malaysia.
"Duopharma Biotech has already established a strong presence in the anti-psychotic sector and is collaborating with our partners to bring in more locally manufactured psychotropic drugs into our pipelines due to their huge market potential,” he added. - Bernama
Singapore Investment
-
-
-
-
All that Glitters Is Gold8 hours ago
-
-
Portfolio (March 30, 2024)11 hours ago
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5 Singapore Stocks Under Pressure22 hours ago
-
-
QAF #77 - 2023 Annual Report23 hours ago
-
-
-
-
-
The Secret To Investing1 day ago
-
-
-
-
-
-
-
-
-
-
The Green U-Turn3 days ago
-
-
-
Week Ahead4 days ago
-
Burnt out!4 days ago
-
-
-
-
Feb 2024 Expenditure4 days ago
-
-
-
-
-
-
-
Not Worth It6 days ago
-
Trip to Legoland6 days ago
-
-
-
-
-
-
-
-
Starting Our Second Property Cycle1 week ago
-
-
-
Position Update1 week ago
-
-
Finance Investment Movement 431 week ago
-
-
-
-
MAS Singapore Gold Vault2 weeks ago
-
-
Gaining And Holding2 weeks ago
-
-
-
-
Book Giveaway- Winners2 weeks ago
-
-
ICYMI: Corporate Connect with Singpost2 weeks ago
-
-
Just sold at record high!3 weeks ago
-
-
-
-
-
-
-
-
-
Monthly IBKR Update – Feb 20243 weeks ago
-
-
Feb 2024 Portfolio3 weeks ago
-
Rethinking my financial targets for 20243 weeks ago
-
-
-
-
Summary of February 20244 weeks ago
-
Portfolio -- Feb 20244 weeks ago
-
The Market Is A Scam!4 weeks ago
-
-
-
-
-
-
-
-
-
-
-
Today’s Deal of the day – Max Miles5 weeks ago
-
-
Options Trading Journal Jan 20241 month ago
-
-
-
-
-
-
-
-
-
-
-
End of 2023 Review2 months ago
-
-
Year 2023 DIYQuant Portfolio Performance Report2 months ago
-
Monthly Summary of November 20233 months ago
-
3 Simple Poker Strategies for Beginners3 months ago
-
Migration of website4 months ago
-
-
Abandon REITS?4 months ago
-
-
-
-
-
-
-
-
-
August 2023 Portfolio Updates6 months ago
-
-
-
-
Hello SP Group, I'm Back!9 months ago
-
-
-
-
I am in debt9 months ago
-
A New Light10 months ago
-
-
-
-
-
-
-
Demoralized1 year ago
-
2022 Thoughts, Hello 2023!1 year ago
-
Series of Defaults for Maple Finance1 year ago
-
Takeaways from “Sea Change”1 year ago
-
-
Greed is Coming Back1 year ago
-
-
-
-
-
-
-
-
-
-
-
What is Overemployment1 year ago
-
-
-
-
-
-
-
-
-
-
-